Thrilled for Day 2 of invigorating discussions on prostate and renal cell cancer at #UromigosLive! by @tompowles1 @brian_rini @Uromigos @OncoAlert @urotoday

Excited to be part of @Uromigos LIVE & UnpluggD ‘25! Can’t wait for the lively, engaging, unfiltered, and insightful conversations that make this meeting so special @OncoAlert

Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!

Proud to endorse my mentor and friend @neerajaiims for the @ASCO Nominating Committee! His humility, kindness, unwavering dedication to mentoring young investigators globally & advancing cancer research inspire me every day. A true leader who lifts everyone around him.

Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on

Thank you Neeraj for reminding us of the importance of accessibility in NGS testing for metastatic prostate cancer. Equity must guide innovation. #IUCS25 @chadihcmd @urologysummit @gbanna74 @ravikanesvaran @OncoAlert @ONCOassist @neerajaiims @PGrivasMDPhD @drenriquegrande

Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on

Congrats to Dr. Chadi Hage Chehade on presenting at #ASCO25 on the timing and use of tumor next-generation sequencing testing for the 5 most common cancers in the U.S., and receiving the Conquer Cancer Merit Award! Check out his interview with @urotoday: https://t.co/AlSHVz6po9

🌟🌎 #GlobalGUFriday 🧬 PARP inhibitors: from ovarian cancer to a pan-tumor approach — Landmark phase III trials transforming care in HRR-mutated tumors. @chadihcmd @ggebraelmd @nsayeghmd @ziremozay @SWOGadvocate @JenniferLitton @umangtalking @neerajaiims 📌 FDA/EMA approvals

PARP inhibitors comprise a therapeutic class that targets PARP proteins involved in DNA repair. This #OpenAccess review of PARP inhibitor approvals emphasizes their efficacy across different cancers based on landmark phase 3 clinical trials. 🔗: https://t.co/gbBffsDw7D

Feeling Incredible honored to receive the #JQTF award!🌟 Huge thanks to my mentors @PGrivasMDPhD & JWright - Always inspired 💯 Grateful to @BladderCancerUS for advancing research & advocacy. 🙏 Congrats @AmandaMyersMD @Anto_cigliola @alexzhuDO @DrAndrewKatims #BCANTT25 👏

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: https://t.co/AOfMsRxtH8

A very informative and detailed discussion on practice changing data and trial updates in bladder cancer by @PGrivasMDPhD #BestOfASCO 2025 in Boise! https://t.co/FRHlrbWoBM

Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 https://t.co/AMqlUvlkNG and https://t.co/W8gO8lWxQo @PCFnews @urotoday @OncoAlert

Real-world data show that only 30% to 40% of patients with the most common cancers receive NGS testing. 🗨️ “The ultimate goal would be for all patients to receive NGS testing earlier in their disease course," - @chadihcmd of @huntsmancancer told Healio. https://t.co/bbHJH8q6TQ

Metformin did not boost survival in metastatic hormone-sensitive prostate cancer. It did ease ADT’s metabolic side effects. Not a game-changer, but still some hope for patient quality of life. #Oncology With very nice editorial by @ggebraelmd @chadihcmd and @neerajaiims

✏️@neerajaiims, @chadihcmd, and Georges Gebrael discuss the STAMPEDE trial in their linked comment See here:

So honored to receive this prestigious award by @eaonc kudos to all investigators/staff who work hard to conduct trials globally! @PrECOGonc @NaomiHaas5 @MonikaJoshimd @JCensits @HutchPresident @nicoleflemingmd @Dr_AmerZeidan @BrainTumorDoc @shilpaonc @OncoAlert @TiansterZhang

Utilization and timing of first tumor next-generation sequencing testing (NGS) in Pts w/ 5 most common cancers in the USA - @chadihcmd et al. @huntsmancancer #ASCO25 Abstract 11014 https://t.co/lWefncor0A #PrecisionMedicine #hemonc #bcsm #crcsm #lcsm #pancsm #pcsm

The majority of patients with the most common advanced or metastatic #cancers in the United States do not undergo next-generation sequencing testing, according to data presented at #ASCO25. Healio spoke with @chadihcmd of @huntsmancancer about the data 👇 https://t.co/bbHJH8q6TQ